Tharimmune, Inc. (NASDAQ:THAR – Get Free Report) saw a large decline in short interest in the month of May. As of May 31st, there was short interest totalling 15,400 shares, a decline of 23.0% from the May 15th total of 20,000 shares. Based on an average daily trading volume, of 29,000 shares, the days-to-cover ratio is presently 0.5 days. Approximately 2.0% of the company’s shares are short sold.
Tharimmune Stock Up 0.3 %
NASDAQ THAR traded up $0.01 during trading on Friday, reaching $3.35. 120,376 shares of the stock traded hands, compared to its average volume of 60,520. The stock’s 50-day moving average price is $5.25 and its 200 day moving average price is $6.36. Tharimmune has a fifty-two week low of $2.75 and a fifty-two week high of $163.09.
Tharimmune (NASDAQ:THAR – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($2.85) earnings per share (EPS) for the quarter.
About Tharimmune
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Stories
- Five stocks we like better than Tharimmune
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- MarketBeat Week in Review – 6/10 – 6/14
- How to Calculate Inflation Rate
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- Trading Halts Explained
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Tharimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tharimmune and related companies with MarketBeat.com's FREE daily email newsletter.
